Healthy SubjectsPhase 2/3HEALSPICNCT06582589
HEALSea Nasal Spray for Prevention of Infections in Children
A Phase 2/3 study testing Healsea Children in people with Healthy Subjects, run by Lallemand Pharma AG at 8 sites in Bulgaria.
Trial summary
Healsea® Children is a class IIa medical device. This is an isotonic seawater-based nasal spray supplemented with a natural Symbiofilm™ extract (0.02%) isolated from marine bacteria. Healsea® Children is indicated in children above 6 years to clean and moisten the nose during colds. Read more about this study
- Who is it for?
- Ages 6 to 17 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Subjects
- What is being tested?
- Healsea Children
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 139 participants
- Where
- 8 sitesBulgaria
- Study dates
- 25 Nov 2024to 23 Apr 2025
- Phase
- Phase 2/3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 6 to 17 years
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Male/Female subjects ≥6 and \<18-year-old
- No respiratory tract infection within 15 days before trial entry and at trial entry
- Written consent obtained from parent/legal guardians
- Written assent obtained from patient
- Availability of a smartphone throughout the study and an internet connection.-
Who cannot join
- Known hypersensitivity/allergy to any component of the test device,
- Subject with severe asthma, perennial allergy, cystic fibrosis, immunodeficiency or ciliary dyskinesis,
- Body temperature ≥ 37.5°
- Medical history or any current disease that is considered by the investigator as a reason for non-inclusion,
- Severe nasal septum deviation or other condition that could cause nasal obstruction such as the presence of nasal polyps,
- Antibiotic (systemic or per nasal route) or antivirals (systemic) intake within 2 weeks before screening,
Show all 13Show fewer
- Systemic or local corticosteroids (nasal route or inhalation) within 4 weeks before screening,
- Antihistamines intake for allergy when treatment was started from less than 4 weeks before screening,
- Vaccination against flu or COVID-19 within 6 months before screening,
- Chronic decongestant use within 2 weeks before screening,
- Bacterial lysates or immunostimulants (food supplements excluded) used for prevention of infection within the 6 months before the screening,
- Prebiotics, probiotics used for prevention of infection within 6 months before the screening,
- Pregnant/Lactating female or with sexual activity without hormonal contraception, intrauterine device or barrier methods.
Trial locations and contacts
8 sites in 1 country.
8 sites in 1 country
Bulgaria8 sites
Multiprofile Hospital for Active Treatment Sveti Ivan Rilski -2003 OOD
Dupnitsa, 2600
Medical Center Plovdimed Ltd
Plovdiv, 4023
Medical Center Iskar EOOD
Sofia, 1000
Medical Center Polymed AD
Sofia, 1303
Medical Center First Pediatric
Sofia, 1404
Multiprofile Hospital for active treatment
Sofia, 1618
Diagnostics and Consultation Center Convex EOOD
Sofia, 1680
Ambulatory for individual Practice for specialized outpatient medical care for children's diseases and pediatric pneumology ans phtysiatry
Vratsa, 3001
About this study
Official title: Efficacy and Safety of Healsea® Children Isotonic Nasal Spray in the Prevention of Upper Respiratory Tract Infections With Nasal Symptoms in Children: a Pre-market Study
Healsea® Children is a class IIa medical device. This is an isotonic seawater-based nasal spray supplemented with a natural Symbiofilm™ extract (0.02%) isolated from marine bacteria. Healsea® Children is indicated in children above 6 years to clean and moisten the nose during colds.
Symbiofilm™, which is not a medicinal product is able to protect the nasal mucosa from viruses' entrance by forming a protective barrier on the nasal mucosa.
Read more
By targeting the nose as entry points for viruses, we hypothesise that Healsea® Children used regularly during the respiratory virus season may prevent upper respiratory tracts infections such as cold or flu with nasal symptoms.
The main objective of this premarket clinical investigation is thus to assess the efficacy of Healsea® Children to prevent upper respiratory tract infections with nasal symptoms in healthy children during 3 treatment periods of 28 days interspersed by 2 wash-out periods of 10 days when compared to children not taking Healsea® Children.
138 children will be randomised in the study, 64 in the Healsea® Children group and 64 in the non-treated group.
The subjects (or their parents) will be asked to report the upper respiratory tract infections with nasal symptoms and complication they may have during the study to the physician in charge of the study conduct.
Two study visits and 3 telephone calls are scheduled. The subjects will also complete an electronic diary to report nasal symptoms and adverse event other than upper respiratory tracts infections.
Read the detailed description
Upper respiratory tract infections (URTIs) and sino-nasal symptoms are very frequent.
Human rhinovirus (more than 100 serotypes) is the most common cause, accounting up to 50% viral rhinitis episodes in children and adults. These episodes can last up to 7-10 days and are usually self-limited. Prevalence of acute rhinosinusitis varies with season (higher in the fall and winter months) and climatic variations and increases with a damp environment and air pollution. It is estimated that an infant can typically have up to 11 upper respiratory tract infection episodes per year with URTIs being one of the main causes of primary care consultations. The number usually diminishes with age, with generally around eight episodes at preschool age and four at school age.
Healsea® Children is a class IIa medical device. This is an isotonic seawater-based nasal spray supplemented with a natural Symbiofilm™ extract (0.02%) isolated from marine bacteria. Healsea® Children is indicated in children above 6 years to clean and moisten the nose during colds and rhinitis. The clinical performance of Healsea® Children is supported by the sea water solution and Symbiofilm™. The exact mechanisms by which nasal irrigation works are not known. However, most of the experts agree that it is primarily a mechanical intervention leading to direct cleaning of the nasal mucosa.
The other component of Healsea® Children, Symbiofilm™ is an exopolymeric composition with emulsifying/surfactant properties which enhance the cleansing and moistening of nasal mucosa. Furthermore, a prophylactic activity of Symbiofilm™ against infection by viruses involved in upper respiratory infections i.e., Adenovirus, Rhinovirus, Flu virus and OC 43 Coronavirus has been demonstrated in vitro on human nasal epithelial cells (HNEpC). The antiviral prophylactic activity of Symbiofilm™ is suggested to rely on its physiochemical properties that, by coating the surface of epithelial cells, hinders the viral entry process, thus explaining the reduced viral adsorption and the subsequent reduced onset of infection.
By targeting the nose as entry points for viruses, we hypothesise that Healsea® Children used regularly during the respiratory virus season may prevent upper respiratory tracts infections with nasal symptoms.
The aim of this two arms prospective randomized open-labelled pre-market clinical investigation, is to establish clinical benefits and clinical safety of Healsea® Children to prevent upper respiratory tract infections with nasal symptoms in healthy children during 3 treatment periods of 28 days (one puff in each ostril twice daily) interspersed by 2 wash-out periods of 10 days when compared to children not taking Healsea® Children.
138 children will be randomised in the study, 64 in the Healsea® Children group and 64 in the non-treated group.
The subjects (or their parents) will be asked to immediately call the investigator in case of nasal symptoms and complication of respiratory infection they may have during the study.
Two study visits (Visit 1, Screening/Randomisation at Day 1 and Visit 2, End of study visit at Day 106 up to Day 116) and 3 telephone calls (telephone call 1 TC1 at Day15 ±3 days, TC2 at Day 55 ±3 days and TC3 at Day 95±3days) are scheduled. The subjects will also complete an electronic diary to report nasal symptoms, device deficiencies, and adverse events other than upper respiratory tracts infections from D2 up to end of study (Day 106 up to Day 116).
The duration of patient's participation is up to 116 days.
- Conditions
- Healthy Subjects
- Being tested
- Healsea Children
- Keywords
- Prevention, Nasal spray, upper respiratory tract infection, saline solution
- Medical subject headings
- Respiratory Tract Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Healsea ChildrenDevice
Subjects will use Healsea Children 1 puff in each nostril twice daily upon awakening and at bedtime, during three 28-day treatment periods interspersed by a 10-day wash-out
| Study group | Role | What they receive |
|---|---|---|
| Healsea Children treated group | Experimental | Subjects of this arm will be treated with Healsea Children nasal spray (1 puff in each nostril twice daily) during 3 treatment periods of 28 days interspersed by 2 wash-out periods of 10 days Receives: Device: Healsea Children |
| untreated group | No intervention | Subjects of this arm will not receive any treatment for the prevention of respiratory tract infection. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of subjects without any upper respiratory tract infection (URTI) with nasal symptoms during the study.
The upper respiratory tracts infections with nasal symptoms (blocked nose, runny nose yellow or green discharge, sneezing ) will be collected for each subject throughout An URTI episode with nasal symptoms is defined as follows: (i) at least 1 of the followings must be present: a blocked nose, runny nose, yellow or green nasal discharge, sneezing; (ii) the symptomatic episode must last for at least 3 days.
Measured: From the randomization up to Day 116
Secondary outcomes (6)
Time to first Upper Respiratory Tract Infection with nasal symptoms during the study
The time to first Upper Respiratory Tract Infection with nasal symptoms (blocked nose, runny nose, yellow or green discharge, sneezing) will be compared between groups
Measured: From the randomization up to Day 116
Number of Upper Respiratory Tract Infections with nasal symptoms during the study
Upper Respiratory Tract Infections with nasal symptoms will be reported by the subjects to the investigators during the whole study duration and the total number compared between groups
Measured: From the randomization up to Day 116
Number of Upper Respiratory Tract Infections complications
Complications of Upper respiratory Tract Infections (bronchitis, bronchiolitis, pneumoniae, pharyngo-tonsillitis, laryngitis, acute otitis) will be reported by the subjects during the whole study duration and compared between groups
Measured: From the randomization up to Day 116
Number of days of use of concomitant treatments that may affect Upper Respiratory Tract Infections symptoms and associated complications
The number of days of antipyretics intake, systemic or local mucolytics, decongestants, antitussives, systemic and per nasal route antibiotics, local and systemic corticosteroids, systemic antivirals) will be compared between the 2 arms
Measured: From the randomization up to Day 116
Number of school days lost due to Upper Respiratory Tract Infections and complications
Number of school days lost due to Upper Respiratory Tract Infections and complications will be collected during the whole study duration and compared between groups
Measured: From the randomization up to Day 116
Assessment of (serious) adverse events and device deficiences throughout the study
Measured: From the randomization up to Day 116
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Sep 2024
- Study start25 Nov 2024
- Primary completion23 Apr 2025
- Study completion23 Apr 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Healthy SubjectsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2/3
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Prospective randomized open label pre-market clinical investigation
- Masking
- None (open label)
- Enrolment
- 139 participants (actual)
Sponsor and investigators
- Lead sponsor
- Lallemand Pharma AG
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06582589
- Sponsor's protocol ID
- LPH-2402
- Other IDs
- 2819/02.08.2024
- Acronym
- HEALSPIC
- Status last verified
- Jul 2025
- First submitted
- 30 Aug 2024
- Last updated
- 22 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Tano L, Tano K. A daily nasal spray with saline prevents symptoms of rhinitis. Acta Otolaryngol. 2004 Nov;124(9):1059-62. doi: 10.1080/00016480410017657.
PubMed 15513550Cabaillot A, Vorilhon P, Roca M, Boussageon R, Eschalier B, Pereirad B. Saline nasal irrigation for acute upper respiratory tract infections in infants and children: A systematic review and meta-analysis. Paediatr Respir Rev. 2020 Nov;36:151-158. doi: 10.1016/j.prrv.2019.11.003. Epub 2020 Feb 21.
PubMed 32312677Stanfel D, Kalogjera L, Ryazantsev SV, Hlaca K, Radtsig EY, Teimuraz R, Hrabac P. The Role of Seawater and Saline Solutions in Treatment of Upper Respiratory Conditions. Mar Drugs. 2022 May 17;20(5):330. doi: 10.3390/md20050330.
PubMed 35621981Slapak I, Skoupa J, Strnad P, Hornik P. Efficacy of isotonic nasal wash (seawater) in the treatment and prevention of rhinitis in children. Arch Otolaryngol Head Neck Surg. 2008 Jan;134(1):67-74. doi: 10.1001/archoto.2007.19.
PubMed 18209140Williamson S, Dennison L, Greenwell K, Denison-Day J, Mowbray F, Richards-Hall S, Smith D, Bradbury K, Ainsworth B, Little P, Geraghty AWA, Yardley L. Using nasal sprays to prevent respiratory tract infections: a qualitative study of online consumer reviews and primary care patient interviews. BMJ Open. 2022 Jun 30;12(6):e059661. doi: 10.1136/bmjopen-2021-059661.
PubMed 35772824
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Efficacy and Safety of Healsea® Children Isotonic Nasal Spray in the Prevention of Upper Respiratory Tract Infections With Nasal Symptoms in Children: a Pre-market Study
- ClinicalTrials.gov ID
- NCT06582589
- Acronym / sponsor ID
- HEALSPIC / LPH-2402
- Conditions
- Healthy Subjects
- Keywords
- Prevention, Nasal spray, upper respiratory tract infection, saline solution
- Phase
- Phase 2/3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 139 participants (actual)
- Lead sponsor
- Lallemand Pharma AGIndustry (pharma, biotech, devices)
- Study start
- 25 Nov 2024 (actual)
- Primary completion
- 23 Apr 2025 (actual)
- Study completion
- 23 Apr 2025 (actual)
- First posted
- 3 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Healsea® Children is a class IIa medical device. This is an isotonic seawater-based nasal spray supplemented with a natural Symbiofilm™ extract (0.02%) isolated from marine bacteria. Healsea® Children is indicated in children above 6 years to clean and moisten the nose during colds.
Symbiofilm™, which is not a medicinal product is able to protect the nasal mucosa from viruses' entrance by forming a protective barrier on the nasal mucosa.
By targeting the nose as entry points for viruses, we hypothesise that Healsea® Children used regularly during the respiratory virus season may prevent upper respiratory tracts infections such as cold or flu with nasal symptoms.
The main objective of this premarket clinical investigation is thus to assess the efficacy of Healsea® Children to prevent upper respiratory tract infections with nasal symptoms in healthy children during 3 treatment periods of 28 days interspersed by 2 wash-out periods of 10 days when compared to children not taking Healsea® Children.
138 children will be randomised in the study, 64 in the Healsea® Children group and 64 in the non-treated group.
The subjects (or their parents) will be asked to report the upper respiratory tract infections with nasal symptoms and complication they may have during the study to the physician in charge of the study conduct.
Two study visits and 3 telephone calls are scheduled. The subjects will also complete an electronic diary to report nasal symptoms and adverse event other than upper respiratory tracts infections.
Detailed description
Upper respiratory tract infections (URTIs) and sino-nasal symptoms are very frequent.
Human rhinovirus (more than 100 serotypes) is the most common cause, accounting up to 50% viral rhinitis episodes in children and adults. These episodes can last up to 7-10 days and are usually self-limited. Prevalence of acute rhinosinusitis varies with season (higher in the fall and winter months) and climatic variations and increases with a damp environment and air pollution. It is estimated that an infant can typically have up to 11 upper respiratory tract infection episodes per year with URTIs being one of the main causes of primary care consultations. The number usually diminishes with age, with generally around eight episodes at preschool age and four at school age.
Healsea® Children is a class IIa medical device. This is an isotonic seawater-based nasal spray supplemented with a natural Symbiofilm™ extract (0.02%) isolated from marine bacteria. Healsea® Children is indicated in children above 6 years to clean and moisten the nose during colds and rhinitis. The clinical performance of Healsea® Children is supported by the sea water solution and Symbiofilm™. The exact mechanisms by which nasal irrigation works are not known. However, most of the experts agree that it is primarily a mechanical intervention leading to direct cleaning of the nasal mucosa.
The other component of Healsea® Children, Symbiofilm™ is an exopolymeric composition with emulsifying/surfactant properties which enhance the cleansing and moistening of nasal mucosa. Furthermore, a prophylactic activity of Symbiofilm™ against infection by viruses involved in upper respiratory infections i.e., Adenovirus, Rhinovirus, Flu virus and OC 43 Coronavirus has been demonstrated in vitro on human nasal epithelial cells (HNEpC). The antiviral prophylactic activity of Symbiofilm™ is suggested to rely on its physiochemical properties that, by coating the surface of epithelial cells, hinders the viral entry process, thus explaining the reduced viral adsorption and the subsequent reduced onset of infection.
By targeting the nose as entry points for viruses, we hypothesise that Healsea® Children used regularly during the respiratory virus season may prevent upper respiratory tracts infections with nasal symptoms.
The aim of this two arms prospective randomized open-labelled pre-market clinical investigation, is to establish clinical benefits and clinical safety of Healsea® Children to prevent upper respiratory tract infections with nasal symptoms in healthy children during 3 treatment periods of 28 days (one puff in each ostril twice daily) interspersed by 2 wash-out periods of 10 days when compared to children not taking Healsea® Children.
138 children will be randomised in the study, 64 in the Healsea® Children group and 64 in the non-treated group.
The subjects (or their parents) will be asked to immediately call the investigator in case of nasal symptoms and complication of respiratory infection they may have during the study.
Two study visits (Visit 1, Screening/Randomisation at Day 1 and Visit 2, End of study visit at Day 106 up to Day 116) and 3 telephone calls (telephone call 1 TC1 at Day15 ±3 days, TC2 at Day 55 ±3 days and TC3 at Day 95±3days) are scheduled. The subjects will also complete an electronic diary to report nasal symptoms, device deficiencies, and adverse events other than upper respiratory tracts infections from D2 up to end of study (Day 106 up to Day 116).
The duration of patient's participation is up to 116 days.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- Prospective randomized open label pre-market clinical investigation
| Arm | Type | Receives |
|---|---|---|
| Healsea Children treated group | Experimental | Device: Healsea ChildrenSubjects of this arm will be treated with Healsea Children nasal spray (1 puff in each nostril twice daily) during 3 treatment periods of 28 days interspersed by 2 wash-out periods of 10 days |
| untreated group | No intervention | –Subjects of this arm will not receive any treatment for the prevention of respiratory tract infection. |
Who may qualify
- Ages
- 6 to 17 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (5 listed)
- Male/Female subjects ≥6 and \<18-year-old
- No respiratory tract infection within 15 days before trial entry and at trial entry
- Written consent obtained from parent/legal guardians
- Written assent obtained from patient
- Availability of a smartphone throughout the study and an internet connection.-
Key exclusion criteria (13 listed)
- Known hypersensitivity/allergy to any component of the test device,
- Subject with severe asthma, perennial allergy, cystic fibrosis, immunodeficiency or ciliary dyskinesis,
- Body temperature ≥ 37.5°
- Medical history or any current disease that is considered by the investigator as a reason for non-inclusion,
- Severe nasal septum deviation or other condition that could cause nasal obstruction such as the presence of nasal polyps,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Healsea ChildrenSubjects will use Healsea Children 1 puff in each nostril twice daily upon awakening and at bedtime, during three 28-day treatment periods interspersed by a 10-day wash-out | Device | Healsea Children treated group |
Primary outcome
Proportion of subjects without any upper respiratory tract infection (URTI) with nasal symptoms during the study.
Time frame: From the randomization up to Day 116
The upper respiratory tracts infections with nasal symptoms (blocked nose, runny nose yellow or green discharge, sneezing ) will be collected for each subject throughout An URTI episode with nasal symptoms is defined as follows: (i) at least 1 of the followings must be present: a blocked nose, runny nose, yellow or green nasal discharge, sneezing; (ii) the symptomatic episode must last for at least 3 days.
6 secondary outcomes
Time to first Upper Respiratory Tract Infection with nasal symptoms during the study
Time frame: From the randomization up to Day 116
Number of Upper Respiratory Tract Infections with nasal symptoms during the study
Time frame: From the randomization up to Day 116
Number of Upper Respiratory Tract Infections complications
Time frame: From the randomization up to Day 116
Number of days of use of concomitant treatments that may affect Upper Respiratory Tract Infections symptoms and associated complications
Time frame: From the randomization up to Day 116
Number of school days lost due to Upper Respiratory Tract Infections and complications
Time frame: From the randomization up to Day 116
Assessment of (serious) adverse events and device deficiences throughout the study
Time frame: From the randomization up to Day 116
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2025.
- Background: PubMed 15513550Tano L, Tano K. A daily nasal spray with saline prevents symptoms of rhinitis. Acta Otolaryngol. 2004 Nov;124(9):1059-62. doi: 10.1080/00016480410017657.
- Background: PubMed 32312677Cabaillot A, Vorilhon P, Roca M, Boussageon R, Eschalier B, Pereirad B. Saline nasal irrigation for acute upper respiratory tract infections in infants and children: A systematic review and meta-analysis. Paediatr Respir Rev. 2020 Nov;36:151-158. doi: 10.1016/j.prrv.2019.11.003. Epub 2020 Feb 21.
- Background: PubMed 35621981Stanfel D, Kalogjera L, Ryazantsev SV, Hlaca K, Radtsig EY, Teimuraz R, Hrabac P. The Role of Seawater and Saline Solutions in Treatment of Upper Respiratory Conditions. Mar Drugs. 2022 May 17;20(5):330. doi: 10.3390/md20050330.
- Background: PubMed 18209140Slapak I, Skoupa J, Strnad P, Hornik P. Efficacy of isotonic nasal wash (seawater) in the treatment and prevention of rhinitis in children. Arch Otolaryngol Head Neck Surg. 2008 Jan;134(1):67-74. doi: 10.1001/archoto.2007.19.
- Background: PubMed 35772824Williamson S, Dennison L, Greenwell K, Denison-Day J, Mowbray F, Richards-Hall S, Smith D, Bradbury K, Ainsworth B, Little P, Geraghty AWA, Yardley L. Using nasal sprays to prevent respiratory tract infections: a qualitative study of online consumer reviews and primary care patient interviews. BMJ Open. 2022 Jun 30;12(6):e059661. doi: 10.1136/bmjopen-2021-059661.
- Individual participant dataSharing planned: Undecided
Related trials for Healthy Subjects
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Not yet recruitingObservational study
Establishment of Biobank of Nasal Epithelium Samples From Healthy Volunteers
Healthy
RecruitingObservational study
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
Graft-Versus-Host Disease, Graft-versus-leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
8 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2/3 study testing Healsea Children in people with Healthy Subjects, run by Lallemand Pharma AG at 8 sites in Bulgaria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 8 sites in Bulgaria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of subjects without any upper respiratory tract infection (URTI) with nasal symptoms during the study. (time frame: From the randomization up to Day 116). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06582589, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2025.